Explore

Homepage

Get back to the homepage

Our science

Clients & partners say about us

Services

See all we can do for you

Our Mission

What we're working for

The team

Team members and partners

Latest news

Read the news and updates

Our Pipelines

ADC Research

Therapeutic delivery system

Vaccines Research

Treat and cure pathologies

Drug Design

Target biological pathways

Peptides Research

Mainly target the cancer cells

Bioconjugation

Turns biomolecule into vehicule

w

WORK WITH US

Our contract research organization, is putting it's Canadian 🇨🇦 lab. Benefit from our talent.

More details.

ACCELERATE, DEVELOP & CREATE

Located in Canada, our team is ready to be part of yours. Makes WASSC a cost-effective contract research organization.

See our services

Address

2650 Maximilien-Chagnon,
Sherbrooke, Qc, Can, J1E 0M8

Contact

(819) 565-4531
info@wassctechnologie.com

#latest news Introducing ADC Expertise: Elevate Your Drug Development with WASSC TECH’s Decade-Long Experience

Introducing ADC Expertise: Elevate Your Drug Development with WASSC TECH’s Decade-Long Experience

In a groundbreaking move that underscores a decade of expertise, WASSC TECH is proud to unveil its latest service offering: ADC Expertise. With a proven track record spanning over 11 years, CEO and Founder Simon Beaudoin has been at the forefront of optimizing ADCs (Antibody-Drug Conjugates) and Defense therapeutics ACCUM™ Technology. Now, WASSC TECH is extending this unparalleled expertise to help transform your drug development journey.

ADCs have revolutionized the field of therapeutics, providing targeted and potent treatments for a range of diseases. With their intricate design and multifaceted challenges, ADCs demand a high level of skill and understanding to achieve their full potential. This is where WASSC TECH’s ADC Expertise steps in, offering a unique opportunity to leverage the insights gained from years of dedication and innovation.

Simon Beaudoin’s visionary leadership has propelled WASSC TECH to the forefront of ADC optimization. For more than a decade, the company has continuously refined its ACCUM™ Technology, setting the benchmark for effective drug delivery systems. The launch of ADC Expertise opens the door for pharmaceutical companies, research institutions, and biotech startups to tap into this wealth of knowledge and elevate their own drug development endeavors.

When it comes to ADCs, every detail matters. From antibody selection to linker chemistry, payload design, and conjugation methods, WASSC TECH’s ADC Expertise covers the entire spectrum of ADC optimization. By partnering with WASSC TECH, you’re not just accessing a service; you’re gaining a strategic ally that is deeply invested in the success of your drug candidates.

Simon Beaudoin, CEO and Founder of WASSC TECH, commented, « Our journey in ADC optimization has been marked by a passion for innovation and a commitment to pushing the boundaries of what’s possible. With ADC Expertise, we’re excited to share our insights and help others navigate the complexities of ADC development. Whether you’re a seasoned player in the field or just venturing into ADCs, we’re here to support your goals. »

The launch of ADC Expertise signifies a new chapter in drug development, where collaboration and shared knowledge pave the way for breakthrough therapies. By harnessing WASSC TECH’s expertise, you can accelerate your drug development timeline, enhance the therapeutic potential of your compounds, and ultimately contribute to advancing healthcare on a global scale.

To learn more about how ADC Expertise can transform your drug development journey, visit the site or reach out to our team. Join us in shaping the future of therapeutics through innovation, experience, and a commitment to excellence.

See other articles :

0 commentaires

Soumettre un commentaire

Dominic du Boulay